Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith A Aberg

Showing results (61-70 of 211) with videos related to

Pageof 22
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2010
Development of national and multiagency HIV care quality measuresMichael A Horberg, Judith A Aberg, Laura W Cheever, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2013
Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of AmericaJudith A Aberg, Joel E Gallant, Khalil G Ghanem, et al.
HIV Clinical Trials|December 17, 2013
Genetic predictors of cervical dysplasia in African American HIV-infected women: ACTG DACS 268Michelle S Cespedes, Sarah L Kerns, Robert S Holzman, et al.
The Journal of Infectious Diseases|November 26, 2002
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failedMaria B Ristig, Jeffrey Crippin, Judith A Aberg, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2013
Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancyMichelle S Cespedes, Delivette Castor, Susan L Ford, et al.
The Lancet. HIV|April 19, 2017
Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trialJudith A Aberg, Craig A Sponseller, Douglas J Ward, et al.
Diabetes/Metabolism Research and Reviews|February 19, 2016
Prediabetes and diabetes among HIV-infected adults in CameroonJohn Y Rhee, Tumi Divine Bahtila, Dennis Palmer, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|May 1, 2012
Risk factors for tuberculin skin test conversion among HIV-infected patients in New York CitySaumil Doshi, Tina Fang Chen, Josue Zapata, et al.
The Open Virology Journal|November 2, 2011
GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected IndividualsEdgar T Overton, Somnuek Sungkanuparph, Michael Klebert, et al.
Clinical Pharmacology and Therapeutics|May 7, 2003
Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitorsCarla B Washington, Charles Flexner, Lewis B Sheiner, et al.
Pageof 22

Showing results (61-70 of 211) with videos related to

Sort By:
Pageof 22
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2010
Development of national and multiagency HIV care quality measuresMichael A Horberg, Judith A Aberg, Laura W Cheever, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2013
Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of AmericaJudith A Aberg, Joel E Gallant, Khalil G Ghanem, et al.
HIV Clinical Trials|December 17, 2013
Genetic predictors of cervical dysplasia in African American HIV-infected women: ACTG DACS 268Michelle S Cespedes, Sarah L Kerns, Robert S Holzman, et al.
The Journal of Infectious Diseases|November 26, 2002
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failedMaria B Ristig, Jeffrey Crippin, Judith A Aberg, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2013
Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancyMichelle S Cespedes, Delivette Castor, Susan L Ford, et al.
The Lancet. HIV|April 19, 2017
Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trialJudith A Aberg, Craig A Sponseller, Douglas J Ward, et al.
Diabetes/Metabolism Research and Reviews|February 19, 2016
Prediabetes and diabetes among HIV-infected adults in CameroonJohn Y Rhee, Tumi Divine Bahtila, Dennis Palmer, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|May 1, 2012
Risk factors for tuberculin skin test conversion among HIV-infected patients in New York CitySaumil Doshi, Tina Fang Chen, Josue Zapata, et al.
The Open Virology Journal|November 2, 2011
GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected IndividualsEdgar T Overton, Somnuek Sungkanuparph, Michael Klebert, et al.
Clinical Pharmacology and Therapeutics|May 7, 2003
Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitorsCarla B Washington, Charles Flexner, Lewis B Sheiner, et al.
Pageof 22